The addition of an anti-invasive agent to complement targeted BRAF inhibition constitutes an additional therapy that may improve patient outcomes by preventing or delaying the dissemination of drug-resistant clones; however, little is known regarding melanoma invasive strategies following BRAF inhibition. The gene discussed is BRAF; the disease is melanoma.